List of Rapivab drug patents

Rapivab is owned by Biocryst.

Rapivab contains Peramivir.

Rapivab has a total of 3 drug patents out of which 0 drug patents have expired.

Rapivab was authorised for market use on 19 December, 2014.

Rapivab is available in solution;intravenous dosage forms.

Rapivab can be used as treatment of acute uncomplicated influenza in patients 2 years and older; treatment of acute uncomplicated influenza in adults; treatment of acute uncomplicated influenza in patients 6 months and older, treatment of acute uncomplicated influenza in patients 2 years and older; treatment of acute uncomplicated influenza in patients 6 months and older.

The generics of Rapivab are possible to be released after 07 May, 2027.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6562861 BIOCRYST Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
Dec, 2023

(10 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10391075 BIOCRYST Antiviral treatments
Feb, 2027

(4 years from now)

US8778997 BIOCRYST Antiviral treatments
May, 2027

(4 years from now)

Drugs and Companies using PERAMIVIR ingredient

Market Authorisation Date: 19 December, 2014

Treatment: Treatment of acute uncomplicated influenza in patients 2 years and older; Treatment of acute uncomplicated influenza in patients 6 months and older; Treatment of acute uncomplicated influenza in adults

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic